Hisamitsu Pharmaceutical Co., Inc. (HTSUF)

Market Cap	2.96B +36.5%
Revenue (ttm)	1.02B +6.1%
Net Income	127.99M +28.6%
EPS	1.77 +32.7%
Shares Out	n/a
PE Ratio	23.11
Forward PE	n/a
Dividend	0.71 (2.44%)
Ex-Dividend Date	Aug 28, 2025

Volume	100
Average Volume	206
Open	29.00
Previous Close	28.94
Day's Range	29.00 - 29.00
52-Week Range	27.52 - 32.30
Beta	0.39
RSI	50.30
Earnings Date	Apr 9, 2026

About HTSUF

Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals in Japan. The company offers OTC products, such as, external pain-relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; BUTENALOCK, a remedy for athlete′s foot; and ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, a transdermal analgesic anti-inflammatory drug; and patches for female hormone, asthma, and overactive bladders. It also exports its products to As...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1847
• Employees: 2,799
• Stock Exchange: OTCMKTS
• Ticker Symbol: HTSUF

Financial Performance

In fiscal year 2025, HTSUF's revenue was 156.01 billion, an increase of 10.09% compared to the previous year's 141.71 billion. Earnings were 21.76 billion, an increase of 55.76%.

Financial numbers in JPY